Frank Speleman

Ghent University — Belgium

Medicine · Health Sciences

83h-index26.4kcitations814works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(404), Cancer, Hypoxia, and Metabolism(108), Protein Degradation and Inhibitors(79), Genomic variations and chromosomal abnormalities(62), Acute Myeloid Leukemia Research(48)

Publications807 total

Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis
JCO Precision Oncology·2026Open Access
Widespread DNA off-targeting confounds studies of RNA chromatin occupancy
2025Open Access
A drug–diet combination could improve childhood cancer treatment
Nature·2025
Stress attenuation by the adrenergic-specific lncRNA NESPR prevents cell death in neuroblastoma cells
2025· 1 cited
Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors
2025Open Access
RUVBL1 and RUVBL2 are druggable MYCN regulators in neuroblastoma
2024Open Access
NBAtlas: A harmonized single-cell transcriptomic reference atlas of human neuroblastoma tumors
Cell Reports·2024· 18 citedOpen Access
Abstract A020 MYCN overexpression biases human sympatho-adrenergic development towards progenitor cells causing neuroblastoma-like tumor xenografts
Cancer Research·2024
HTSplotter: An end-to-end data processing, analysis and visualisation tool for chemical and genetic in vitro perturbation screening
PLoS ONE·2024· 10 citedOpen Access
Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN
NAR Cancer·2023· 3 citedOpen Access
MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression
Oncogene·2023· 8 citedOpen Access
RUVBL1 and RUVBL2 as novel druggable DNA Damage Response regulators in the N-Myc regulatory network in neuroblastoma
2023· 1 citedOpen Access
Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma
International Journal of Molecular Sciences·2023Open Access
Human iPSC modeling recapitulates in vivo sympathoadrenal development and reveals an aberrant developmental subpopulation in familial neuroblastoma
iScience·2023· 7 citedOpen Access
Preclinical exploration of the DNA Damage Response pathway using the interactive neuroblastoma cell line explorer CLEAN
2023· 1 citedOpen Access
Supplementary Methods, Tables 1-2, Figures 1-3 from Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
2023Open Access
Data from Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
2023Open Access
Data from Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
2023Open Access
Supplementary Methods, Tables 1-2, Figures 1-3 from Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
2023Open Access
Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
page 1 of 41Next →

Frequent Co-authors

Jo Vandesompele(21), Katleen De Preter(12), Geneviève Laureys(11), Nadine Van Roy(11), Angelika Eggert(9), Alexander Schramm(9), Pieter Mestdagh(8), Frank Westermann(8), Johannes H. Schulte(8), Pieter Van Vlierberghe(7), Björn Menten(7), Joëlle Vermeulen(7), Anne De Paepe(6), Gudrun Schleiermacher(6), Isabelle Janoueix‐Lerosey(6), Olivier Delattre(6), Matthias Fischer(6), Geert Mortier(5), Joris Vermeesch(5), Valérie Combaret(5)